Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer

NCT01598077 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01598077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01598077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
March 31, 2014
Enrollment
54 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, her2 + breast cancer, her2 + breast cancer, her2 + gastric cancer, squamous cell carcinoma of head and neck, esophageal squamous cell carcinoma, her2 + gastric cancer, squamous cell carcinoma of head and neck